. KubiakDW, SzumitaPM, FanikosJR. Extensive prolongation of aPTT with argatroban in an elderly patient with improving renal function, normal hepatic enzymes, and metastatic lung cancer. Ann Pharmacother2005; 39: 1119–23. Epub 10 May 2005. DOI 10.1345/aph.1G020
2.
. Product information. Argatroban. Research Triangle Park, NC: GlaxoSmithKline Beecham, February 2002.
3.
. GosselinRC, DagerWE, KingJH, JanatpourK, MahackianK, LarkinEC, Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban on prothrombin time and INR values. Am J Clin Pathol2004; 121: 593–9.
4.
. ShethSB, DiciccoRA, HurstingMJ, MontaguetT, JorkaskyDK. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost2001; 85: 435–40.
5.
. HurstingMJ, ZehnderJL, JoffrionJL, BeckerJC, KnappenbergerGD, SchwarzRP. The international normalized ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used. Clin Chem1999; 45: 409–12.
6.
. Product information. Coumadin (warfarin). Wilmington, DE: Du Pont Pharmaceuticals, revised 11/99, reviewed 7/2000.
7.
. KearonC, JohnstonM, MoffatK, McGinnisJ, GinsbergJS. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med1998; 158: 1140–3.
8.
. HarderS, GraffJ, KlinkhardtU, von HentigN, WalengaJM, WatanabeH, Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and ecarin clotting time. Thromb Haemost2004; 91: 1137–45.
9.
. SchünemannHJ, MungerH, BrowerS, O'DonnellM, CrowtherM, CookD, Methodology for guideline development for the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest2004; 126 (3 suppl): 174S–8S.